Da traduttori professionisti, imprese, pagine web e archivi di traduzione disponibili gratuitamente al pubblico.
masitinib
mazitinibs
Ultimo aggiornamento 2014-11-21
Frequenza di utilizzo: 2
Qualità:
masitinib 150 mg
masitinibs 150 mg
Ultimo aggiornamento 2017-04-26
Frequenza di utilizzo: 6
Qualità:
masitinib 150 mg colourants (e171, e 110)
masitinibs 150 mg krāsvielas (e 171, e 110)
Ultimo aggiornamento 2012-04-10
Frequenza di utilizzo: 4
Qualità:
masitinib is metabolised predominantly by n-dealkylation.
masitinibs tiek metabolizēts galvenokārt ar n-dealkilēšanu.
Ultimo aggiornamento 2017-04-26
Frequenza di utilizzo: 3
Qualità:
masivet 150 mg film-coated tablets for dogs masitinib
masivet 150 mg apvalkotās tabletes suņiem masitinib
Ultimo aggiornamento 2017-04-26
Frequenza di utilizzo: 1
Qualità:
masitinib is approximately 93 % bound to plasma proteins.
aptuveni 93 % masitiniba saistās ar plazmas proteīniem.
Ultimo aggiornamento 2017-04-26
Frequenza di utilizzo: 3
Qualità:
masitinib 150 mg (equivalent to masitinib mesylate 178.9 mg)
150 mg masitiniba (ekvivalents 178, 9 mg masitiniba mezilāta).
Ultimo aggiornamento 2012-04-10
Frequenza di utilizzo: 2
Qualità:
Attenzione: Questo allineamento potrebbe essere errato.
Eliminalo se ritieni che sia così.
people with known hypersensitivity to masitinib should not handle the product.
cilvēki, kuriem ir zināma paaugstināta jutība pret masitinibu, nedrīkst rīkoties ar šīm zālēm.
Ultimo aggiornamento 2017-04-26
Frequenza di utilizzo: 3
Qualità:
repeated dermal contact with masitinib may impair female fertility and foetal development.
atkārtots masitiniba kontakts ar ādu var vājināt sieviešu auglību un augļa attīstību.
Ultimo aggiornamento 2017-04-26
Frequenza di utilizzo: 3
Qualità:
each tablet contains either 50mg or 150 mg of masitinib, which is the active substance.
katra tablete satur 50 mg vai 150 mg masitiniba, kas ir aktīvā viela.
Ultimo aggiornamento 2017-04-26
Frequenza di utilizzo: 2
Qualità:
to date, other potential risks associated with long-term treatment with masitinib are unknown
līdz šim nav zināmi citi iespējamie riski, kas saistīti ar ilgtermiņa ārstēšanu ar masitinibu
Ultimo aggiornamento 2015-07-30
Frequenza di utilizzo: 1
Qualità:
Riferimento:
masivet contains masitinib, which belongs to a class of medicines having an anticancer action.
masivet satur mazitinibu, kas pieder pie zāļu grupas ar pretvēža iedarbību.
Ultimo aggiornamento 2017-04-26
Frequenza di utilizzo: 3
Qualità:
Riferimento:
has an allergic reaction to masitinib, the active ingredient of masivet or an excipient used in this medicine.
sunim ir alerģiska reakcija uz masitinibu, kas ir masivet aktīvā sastāvdaļa, vai uz kādu no palīgvielām, kas lietotas šajās zālēs.
Ultimo aggiornamento 2012-04-10
Frequenza di utilizzo: 1
Qualità:
Riferimento:
concurrent use of other substances with a high degree of protein binding may compete with masitinib binding and thus cause adverse effects.
vienlaicīga citu vielu lietošana, kuras stingrāk saistās ar proteīniem, var radīt konkurenci masitiniba saistīšanai un tādā veidā izraisīt nevēlamus efektus.
Ultimo aggiornamento 2017-04-26
Frequenza di utilizzo: 3
Qualità:
Riferimento:
it should not be used in dogs that may be hypersensitive (allergic) to masitinib or any of the other ingredients.
to nedrīkst lietot suņiem, kam ir paaugstināta jutība (alerģija) pret mazitinibu vai kādu citu šo zāļu sastāvdaļu.
Ultimo aggiornamento 2017-04-26
Frequenza di utilizzo: 3
Qualità:
Riferimento:
response to treatment with masitinib was expressed as stable disease; i.e. static, partial or complete response.
reakcija uz ārstēšanu ar masitinibu izpaudās kā stabila slimība, t.i., statiska, daļēja vai pilnīga reakcija.
Ultimo aggiornamento 2017-04-26
Frequenza di utilizzo: 3
Qualità:
Riferimento:
masitinib treatment should only be used in dogs with non-resectable mast cell tumours and which express the mutated c-kit tyrosine kinase receptor.
Ārstēšanu ar masitinibu drīkst lietot tikai suņiem ar neoperējamiem tuklo šūnu audzējiem, kuri ekspresē mutējušu c-kit tirozīna kināzes receptoru.
Ultimo aggiornamento 2017-04-26
Frequenza di utilizzo: 3
Qualità:
Riferimento:
masitinib treatment should only be used in dogs with non-resectable mast cell tumours, which express the mutated c-kit tyrosine kinase receptor.
Ārstēšanu ar masitinibu drīkst lietot tikai suņiem ar neoperējamiem tuklo šūnu audzējiem, kuri ekspresē mutējušu c-kit tirozīna kināzes receptoru.
Ultimo aggiornamento 2017-04-26
Frequenza di utilizzo: 3
Qualità:
Riferimento:
masitinib 50 mg (equivalent to masitinib mesylate 59.6 mg) masitinib 150 mg (equivalent to masitinib mesylate 178.9 mg)
50 mg masitiniba (kas atbilst 59,6 mg masitiniba mezilāta) 150 mg masitiniba (kas atbilst 178,9 mg masitiniba mezilāta)
Ultimo aggiornamento 2017-04-26
Frequenza di utilizzo: 1
Qualità:
Riferimento:
overdosing signs were observed in toxicity studies conducted in healthy dogs, treated for 39 weeks at doses of around 2 times the recommended dose (25 mg masitinib), treated for 13 weeks and 4 weeks at doses of around 3 times the recommended dose (41.7 mg masitinib), and treated for 4 weeks at doses of around 10 times the recommended dose (125 mg masitinib).
pārdozēšanas pazīmes novēroja toksicitātes pētījumos ar veseliem suņiem, kuri 39 nedēļas saņēma devu, kas aptuveni 2 reizes pārsniedza ieteicamo devu (25 mg masitiniba), kuri 13 nedēļas un 4 nedēļas saņēma aptuveni 3 reizes augstāku devu nekā ieteicamā deva (41,7 mg masitiniba), un kuri 4 nedēļas saņēma aptuveni 10 reizes augstāku devu nekā ieteicamā deva (125 mg masitiniba).
Ultimo aggiornamento 2017-04-26
Frequenza di utilizzo: 3
Qualità:
Riferimento: